CYP2D plays a major role in berberine metabolism in liver of mice and humans

Xenobiotica

Volumn 41, Issue 11, 2011, Pages 996-1005

  Guo, Ying ^a,b   Li, Feng ^b   Ma, Xiaochao ^b   Cheng, Xingguo ^b   Zhou, Honghao ^a   Klaassen, Curtis D ^b  

^a Central South University   (China)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Berberine; Humans; Liver; Metabolism; Mice

Indexed keywords

BERBERINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; FURAFYLLINE; KETOCONAZOLE; PAROXETINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TRANSFORMATION; ENZYME INHIBITION; FECES ANALYSIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER METABOLISM; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PHARMACOGENETICS; URINALYSIS;

ANIMALS; BERBERINE; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; FECES; HUMANS; LIVER; MALE; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; RECOMBINANT PROTEINS;

MUS;

EID: 80053992713     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.597456     Document Type: Article

References (30)

1. Abourashed EA, Khan IA. (2001). High-performance liquid chromatography determination of hydrastine and berberine in dietary supplements containing goldenseal. J Pharm Sci 90:817-822. (Pubitemid 32645940)
2. Amin AH, Subbaiah TV, Abbasi KM. (1969). Berberine sulfate: antimicrobial activity, bioassay, and mode of action. Can J Microbiol 15:1067-1076.
3. Barnes PM, Bloom B, Nahin RL. (2008). Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report: 1-23.
4. Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B. (2000). Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131-1152. (Pubitemid 32368013)
5. Deroussent A, Ré M, Hoellinger H, Cresteil T. (2010). Metabolism of sanguinarine in human and in rat: characterization of oxidative metabolites produced by human CYP1A1 and CYP1A2 and rat liver microsomes using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 52:391-397.
6. Evans WE, Relling MV. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491.
7. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. (1997). Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 7:391-396. (Pubitemid 27427549)
8. Hoshi A, Ikekawa T, Ikeda Y, Shirakawa S, Iigo M. (1976). Antitumor activity of berberrubine derivatives. Gann 67:321-325.
9. Hua W, Ding L, Chen Y, Gong B, He J, Xu G. (2007). Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal 44:931-937. (Pubitemid 47095187)
10. Kobayashi Y, Yamashita Y, Fujii N, Takaboshi K, Kawakami T, Kawamura M, Mizukami T, Nakano H. (1995). Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes. Planta Med 61:414-418.
11. Krishnan P, Bastow KF. (2000). The 9-position in berberine analogs is an important determinant of DNA topoisomerase II inhibition. Anticancer Drug Des 15:255-264. (Pubitemid 32096152)
12. Kunze KL, Trager WF. (1993). Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649-656. (Pubitemid 23290017)
13. Lahiri SC, Dutta NK. (1967). Berberine and chloramphenicol in the treatment of cholera and severe diarrhoea. J Indian Med Assoc 48:1-11.
14. Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J. (2002). CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 22:1001-1006. (Pubitemid 34831295)
15. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C, Gosby A, Kraegen EW, James DE, Kim JB. (2006). Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55:2256-2264. (Pubitemid 44743622)
16. Li F, Wang L, Guo GL, Ma X. (2010). Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos 38:871-878.
17. Li Y, Ren G, Wang YX, Kong WJ, Yang P, Wang YM, Li YH, Yi H, Li ZR, Song DQ, Jiang JD. (2011). Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes. J Transl Med 9:62.
18. Liu YT, Hao HP, Xie HG, Lai L, Wang Q, Liu CX, Wang GJ. (2010). Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos 38:1779-1784.
19. Molanaei H, Carrero JJ, Heimbürger O, Nordfors L, Lindholm B, Stenvinkel P, Odar-CederlÖf I, Bertilsson L. (2010). Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. Eur J Clin Pharmacol 66:269-273.
20. Pan JF, Yu C, Zhu DY, Zhang H, Zeng JF, Jiang SH, Ren JY. (2002). Identification of three sulfate-conjugated metabolites of berberine chloride in healthy volunteers' urine after oral administration. Acta Pharmacol Sin 23:77-82. (Pubitemid 34073273)
21. Qiu F, Zhu Z, Kang N, Piao S, Qin G, Yao X. (2008). Isolation and identification of urinary metabolites of berberine in rats and humans. Drug Metab Dispos 36:2159-2165.
22. Sandson N. (2005). Drug-drug interactions: the silent epidemic. Psychiatr Serv 56:22-24. (Pubitemid 40094463)
23. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
24. Thummel KE, Wilkinson GR. (1998). In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430. (Pubitemid 28231501)
25. Tsai PL, Tsai TH. (2004). Hepatobiliary excretion of berberine. Drug Metab Dispos 32:405-412.
26. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, Taketo MM, Cooney GJ, Kraegen EW, James DE, Hu LH, Li J, Ye JM. (2008). Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57:1414-1418.
27. Vuddanda PR, Chakraborty S, Singh S. (2010). Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opin Investig Drugs 19:1297-1307.
28. Wang H, Liu D, Cao P, Lecker S, Hu Z. (2010). Atrogin-1 affects muscle protein synthesis and degradation when energy metabolism is impaired by the antidiabetes drug berberine. Diabetes 59:1879-1889.
29. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. (1987). Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036. (Pubitemid 18075638)
30. Zuo F, Nakamura N, Akao T, Hattori M. (2006). Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos 34:2064-2072. (Pubitemid 44837767)